A collaborative study at The Jackson Laboratory employed genetically diverse mouse models to elucidate how inherited variation affects tumor response to immune checkpoint inhibitors. Their findings demonstrate gene-specific impacts on therapeutic outcomes, mirroring challenges in human genome-wide association studies due to complex genetic backgrounds. This work advances precision oncology by improving patient stratification for immunotherapy efficacy based on genetic profiles.